{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Preleukemia&page=5", "query": { "condition": "Preleukemia", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1784, "total_pages": 179, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Preleukemia&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Preleukemia&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T18:09:03.705Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01300611", "title": "TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Double Cord Blood Transplant", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Myelofibrosis", "Acute Lymphoblastic Leukemia", "Chronic Myelocytic Leukemia", "Non Hodgkins Lymphoma", "Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "TXA127 300 mcg/kg/day", "type": "DRUG" }, { "name": "TXA127 1000 mcg/kg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarix Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300611" }, { "nct_id": "NCT02981914", "title": "Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Classical Hodgkin Lymphoma", "B-cell Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-03-07", "completion_date": "2020-11-01", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981914" }, { "nct_id": "NCT03682536", "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" }, { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2019-01-02", "completion_date": "2027-09-28", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 25, "location_summary": "Berkeley, California • San Diego, California • Whittier, California + 22 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682536" }, { "nct_id": "NCT01335165", "title": "Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Paroxysmal Nocturnal Hemoglobinuria (PNH)" ], "interventions": [ { "name": "ALXN1102", "type": "DRUG" }, { "name": "ALXN1103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335165" }, { "nct_id": "NCT00943800", "title": "Combined Haploidentical-Cord Blood Transplantation for Adults and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Myelodysplastic Syndrome", "Multiple Myeloma", "Lymphoma" ], "interventions": [ { "name": "Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Stem Cells Collections", "type": "PROCEDURE" }, { "name": "Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Fludarabine, Busulfan, and ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 87, "start_date": "2006-10-09", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943800" }, { "nct_id": "NCT07283900", "title": "Ascorbate in Myelodysplastic Syndrome", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "High-dose ascorbate", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prajwal Dhakal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 38, "start_date": "2026-03-11", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283900" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT00265837", "title": "Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 72, "start_date": "2002-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265837" }, { "nct_id": "NCT00004239", "title": "506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Compound 506U78", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "1999-12", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2016-07-04", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 3, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Winston-Salem, North Carolina", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004239" }, { "nct_id": "NCT03647800", "title": "Study of APVO436 in Patients With AML or MDS", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "MDS" ], "interventions": [ { "name": "APVO436", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aptevo Research and Development LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2018-12-13", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2022-02-10", "last_synced_at": "2026-10-23T18:09:03.705Z", "location_count": 12, "location_summary": "San Francisco, California • Denver, Colorado • Gainesville, Florida + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647800" } ] }